1. Origin and Structural Characteristics
Body Protection Compound-157 (BPC-157) is a synthetic 15-amino acid peptide derived from a naturally occurring gastric juice protein known as Body Protection Compound (BPC). Unlike most native linear peptides that degrade within minutes in the harsh acidic environment of the stomach, BPC-157 exhibits remarkable structural resistance to gastric proteases, maintaining chemical integrity for over 24 hours in gastric juice ($\text{pH } 1.0 - 2.0$).
2. Mechanism of Action: Angiogenesis & Growth Factor Upregulation
The biological activity of BPC-157 is primarily mediated through several interconnected pathways:
- VEGFR2 Activation: BPC-157 promotes the activation and internalization of vascular endothelial growth factor receptor 2 (VEGFR2), triggering rapid capillary sprouting (angiogenesis) to re-vascularize avascular and ischemic tissues.
- Modulation of Nitric Oxide (NO) System: Research by Sikiric et al. demonstrated that BPC-157 acts as a dual-regulator of nitric oxide, normalizing both endothelial NOS (eNOS) deficiency and inducible NOS (iNOS) hyperactivity.
- FAK-Paxillin Signaling: In vitro tendon fibroblast studies reveal that BPC-157 stimulates the focal adhesion kinase (FAK) and paxillin pathway, accelerating dose-dependent tendon outgrowth and migration.
- Collagen Type I Synthesis: Promotes enhanced expression of Col1a1 and early growth response protein 1 (Egr-1), critical for tendon-to-bone junction remodeling.
"BPC-157 promoted the ex vivo outgrowth of tendon fibroblasts from tendon explants, increased cell survival under oxidative stress, and enhanced in vitro migration of tendon fibroblasts via the FAK-paxillin pathway." (Chang et al., J Appl Physiol, 2011).
3. Gastrointestinal Mucosal Defense & IBD Models
In preclinical gastroenterology research, BPC-157 exhibits profound mucosal healing effects:
NSAID-Induced Lesion Reversal
Protects against and reverses severe gastric ulceration caused by indomethacin, aspirin, and celecoxib without suppressing baseline stomach acid production.
Gut Barrier Integrity
Upregulates tight junction proteins (Claudin-1, ZO-1), attenuating systemic endotoxemia in murine models of ulcerative colitis and leaky gut syndrome.
4. Research Protocols & Dosage Guidelines
In laboratory animal and experimental literature, typical research dose concentrations range between:
- Systemic Research Range: $2.5 - 10 \, \mu\text{g} / \text{kg}$ of subject mass, typically administered once or twice daily.
- Standard Laboratory Vial Size: 5 mg lyophilized cake reconstituted with 2.0 mL bacteriostatic water yields $2,500 \, \mu\text{g} / \text{mL}$ ($25 \, \mu\text{g}$ per insulin syringe unit).
📚 Peer-Reviewed Scientific References
- Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease." Curr Pharm Des. 2011;17(16):1612-32. PMID: 21548867.
- Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Appl Physiol. 2011;110(3):774-80. PMID: 21030672.
- Hsieh PC, et al. "Therapeutic potential of pentadecapeptide BPC 157 on Achilles tendon healing in rats." J Orthop Res. 2020;39(3):600-610. PMID: 32667746.
- Vukojevic J, et al. "Pentadecapeptide BPC 157 and the central nervous system." Neural Regen Res. 2018;13(11):1981-1987. PMID: 30238995.